Genetic Testing for Epilepsy: Sequence Analysis and Exon-Level Deletion/Duplication Testing of up to 127 Genes

Tests Included:

- Comprehensive Epilepsy Panel
- Infantile Epilepsy Panel
- Childhood Epilepsy Panel
- STAT Epilepsy Panel
- Progressive Myoclonic Epilepsy Panel
- Rett/Angelman Syndrome Epilepsy Panel

Clinical Features:

Epilepsy is defined by the occurrence of at least two unprovoked seizures occurring more than 24 hours apart. It is a common neurological disorder that affects at least 0.8% of the population. The International League against Epilepsy (ILAE) classifies seizures into two main categories.[1] **Generalized epileptic seizures** originate in and rapidly engage both cerebral hemispheres. Tonic-clonic, absence, myoclonic, clonic, tonic, and atonic seizures are all types of generalized seizures. **Focal seizures** originate from neuronal networks within a single hemisphere. Traditionally, focal seizures have been classified as “simple partial seizures,” which do not result in an alteration of consciousness, and “complex partial seizures,” which cause a change in behavior or consciousness.

Some types of seizures, such as infantile spasms, do not fit into either category and remain unclassified. Seizures can be self-limiting or controlled by standard therapeutic treatments in some cases; however, individuals with epileptic encephalopathy have severe seizures that are refractory to treatment, leading to cognitive and behavioral impairment secondary to the epileptic activity. Epilepsy may be an isolated neurological symptom, or it may occur in association with other neurological symptoms or medical problems.[2] Some individuals with epilepsy are diagnosed with an electroclinical syndrome such as West or Ohtahara syndrome based on the presence of characteristic EEG findings and the clinical and family history.[1]

Inheritance Pattern/Genetics:

Epilepsy can be caused by genetic disorders, metabolic diseases, trauma, infection, and structural brain abnormalities, although the cause is not known in many cases. A genetic etiology underlies epilepsy in approximately 40% of individuals.[3] Genes have been identified that cause both generalized seizures and focal seizures, as well as unclassified epilepsy types such as infantile spasms. The genetic etiology of idiopathic generalized epilepsy (IGE) is

frequently complex because it is due to a combination of multiple genetic factors that each confer a small risk for epilepsy and may be modified by environmental influences.[3] Currently, approximately 2% of patients with IGE harbor an identifiable variant in a single gene associated with Mendelian inheritance of epilepsy.[4] However, the percentage of patients with Mendelian epilepsy is higher for specific epilepsy types such as infantile spasms, benign familial neonatal and neonatal-infantile seizures (BFNS and BFNIS), and others.[3,5,6,7] The inheritance pattern can be autosomal dominant, autosomal recessive, or X-linked. Pathogenic variants in a single gene may be associated with different types of seizures (clinical heterogeneity), and conversely, pathogenic variants in different genes can cause the same epilepsy phenotype (genetic heterogeneity).

The Epilepsy Panels at GeneDx includes sequencing and deletion/duplication analysis of genes causing Mendelian forms of epilepsy. Many of these genes encode subunits of ion channels involved in stabilizing or propagating neuronal activity, including components of the voltage-gated sodium, potassium, and calcium channels and the ligand-gated gamma-aminobutyric (GABA) channel.[5,7,8,9] The panels also includes non-ion channel genes associated with a variety of neurotransmitter disorders, storage and other neurometabolic disorders, as well as genes causing syndromic forms of epilepsy, many of which are involved in transcriptional activation or repression. [5,6,8,10,11,12]

Several different Epilepsy Panels are available at GeneDx, based on seizure age-of-onset and/or clinical presentation. The complete list of genes included on each panel is included in the table in the appendix. Available panels include:

- Comprehensive Epilepsy Panel (127 genes)
- Infantile Epilepsy Panel (111 genes)
- Childhood Epilepsy Panel (84 genes)
- STAT Epilepsy Panel* (26 genes, many with treatment implications)
- Progressive Myoclonic Epilepsy Panel* (18 genes)
- Rett/Angelman Syndrome Panel*

* Separate information sheets are available on our website (www.genedx.com) with more specific information about our STAT Epilepsy, Rett/Angelman Syndrome, and Progressive Myoclonic Epilepsy testing panels. In addition to the epilepsy panels mentioned above, GeneDx also offers panels or single gene testing for many other disorders causing epilepsy, such as tuberous sclerosis complex, mitochondrial disorders, and metabolic disorders.

Test Methods:
Using genomic DNA from the submitted specimen, the complete coding regions and splice site junctions of the genes on this panel are enriched using a proprietary targeted capture system

developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNV). The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons; however, technical limitations and inherent sequence properties effectively reduce this resolution for some genes. Alternative sequencing or copy number detection methods are used to analyze or confirm regions with inadequate sequence or copy number data by NGS. Reportable variants include pathogenic variants, likely pathogenic variants and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request.

The technical sensitivity of sequencing is estimated to be > 99% at detecting single nucleotide events. It will not reliably detect deletions greater than 20 base pairs, insertions or rearrangements greater than 10 base pairs, or low-level mosaicism. The copy number assessment methods used with this test cannot reliably detect copy number variants of less than 500 base pairs or mosaicism and cannot identify balanced chromosome aberrations. Assessment of exon-level copy number events is dependent on the inherent sequence properties of the targeted regions, including shared homology and exon size. For the CHRNA7, MAGI2, and PLCB1 gene(s), deletion/duplication analysis, but not sequencing was performed. For the DNM1, FOXG1, and SLC6A8 gene(s), sequencing but not deletion/duplication analysis, was performed. If indicated based on the patient's specific clinical features, multiplex ligation-dependent probe amplification (MLPA) of the FOXG1 and SLC6A8 genes is available as a separate test (test code 906).

Test Sensitivity:

The clinical sensitivity of sequencing and deletion/duplication analysis of the genes included in the Comprehensive Epilepsy Panel depends in part on the patient's clinical phenotype. In a prior study, 31% of individuals with infantile spasms who were tested using an epilepsy gene panel were found to harbor definitive pathogenic variant(s) to explain the phenotype (Wirrell et al., 2015). Overall, 17-20% of epileptic encephalopathies have an identifiable genetic etiology (EpiPM Consortium, 2015). Specific information about the diagnostic yield for each gene in selected populations is summarized in the table below.

Diagnostic Yield of Epilepsy Panel Genes in Selected Populations

Epilepsy Type	Gene	Protein	Inh	Diagnostic Yield in Selected Population(s)
Benign familial neonatal seizures (BFNS)	*KCNQ2*	Potassium voltage-gated channel subfamily KQT member 2	AD	>50% BFNS[6]
	KCNQ3	Potassium voltage-gated channel subfamily KQT member 3	AD	~7% BFNS[6]
Benign familial neonatal-infantile seizures (BFNIS)	*SCN2A*	Sodium channel protein type 2 subunit alpha	AD	Unknown[6]
Benign familial infantile seizures (BFIS)	*PRRT2*	Proline-rich transmembrane protein 2	AD	83% familial and 30% sporadic BFIS[14,15,16]; 62-96% of familial PKD/IC; 36% sporadic PKD/IC[14,17,18]
Familial infantile myoclonic epilepsy (FIME)	*TBC1D24*	TBC1 domain family member 24	AR	Unknown[19,20]
Early-onset epileptic encephalopathy and/or infantile spasms (includes West and Ohtahara syndromes)	*CDKL5*	Cyclin-dependent kinase-like 5	XL	10-17% infantile spasms[6]
	ARX	Aristaless related homeobox	XL	5% males with infantile spasms[6]
	TSC1	Hamartin	AD	2-4% infantile spasms[21,22,23]
	TSC2	Tuberin	AD	10-16% infantile spasms[21,22,23]
	SCN1A	Sodium channel protein type 1 alpha	AD	70-80% Dravet syndrome[6]; 20-24% early-onset cryptic epilepsy[24,25]
	PCDH19	Protocadherin-19	XL	2-14% females with infantile/childhood epilepsy[26,27,28,29,30]
	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	AD	10% neonatal epileptic encephalopathy[31]
	STXBP1	Syntaxin binding protein 1	AD	35% Ohtahara syndrome[6]; Unknown in Dravet syndrome[88]
	SLC2A1	Solute carrier family 2, facilitated glucose transporter member 1	AD	91% GLUT1 deficiency[3]; ~10% early-onset absence epilepsy[6]
	SLC6A1	Solute carrier family 6 member 1	AD	4% myoclonic-astatic epilepsy (MAE)[149]
	STX1B	Syntaxin 1B	AD	Rare in MAE and fever-associated epilepsy syndromes[149]
	ALDH7A1	Alpha-aminoadipic semialdehyde dehydrogenase (antiquitin)	AR	>90% pyridoxine-responsive epilepsy[32]
	POLG	DNA polymerase subunit gamma-1	AR	63-87% Alpers syndrome[33,34,35]; 4-5% infantile/childhood epileptic encephalopathy[34]
	MEF2C	Myocyte-specific enhancer factor 2C	AD	2% epileptic encephalopathy[36]
	SCN2A	Sodium channel protein type 2 alpha	AD	1-2% early-onset epileptic encephalopathy[37,38]
	SCN8A	Sodium channel protein type 8 subunit alpha	AD	Unknown[39]
	CHD2	Chromodomain helicase DNA binding protein 2	AD	1% of epileptic encephalopathy[91]
	*DNM1***	Dynamin 1	AD	1% of epileptic encephalopathy[92]
	GABRA1	Gamma-aminobutyric acid receptor subunit alpha-1	AD	Unknown in Dravet syndrome[88]
	KCNT1	Potassium channel, sodium activated subfamily T, member 1	AD	35% MMPSI[99-101]; Rare in other epileptic encephalopathies[99]
	GRIN2B	Glutamate receptor ionotropic, NMDA 2B	AD	Rare[90]
	GRIN1	Glutamate receptor, ionotropic, NMDA 1	AD	Rare[94]
	CASK	Peripheral plasma membrane protein CASK	XL	~96% females with MICPCH, Rare in epileptic encephalopathy[151]
	SYNGAP1	Ras/Rap GTPase-activating protein SynGAP	AD	Rare[151]
	GABBR2	Gamma-aminobutyric acid type B receptor subunit 2	AD	Rare in epileptic encephalopathy and

Epilepsy Type	Gene	Protein	Inh	Diagnostic Yield in Selected Population(s)
				intellectual disability with Rett-like features[118]
	GABRB2	Gamma-aminobutyric acid (GABA) A receptor, beta 2	AD	Rare[112]
	GABRB3	Gamma-aminobutyric acid (GABA) A receptor, beta 3	AD	Rare[95]
	KCNA2	Potassium voltage-gated channel subfamily A member 2	AD	Rare[138]
	KCNB1	Potassium channel, voltage gated shab related subfamily B, member 1	AD	Rare[98]
	SMC1A	Structural maintenance of chromosomes protein 1A	AD	Rare[151,152]
	PNPO	Pyridoxine-5'-phosphate oxidase	AR	Rare[40]
	SPTAN1	Alpha-II spectrin	AD	Rare[41]
	ALG13	ALG13, UDP-N-acetylglucosaminyltransferase subunit	XL	Rare[92]
	ARHGEF9	Cdc42 guanine nucleotide exchange factor (GEF) 9	XL	Rare[94]
	BRAT1	BRCA1 associated ATM activator 1	AR	Rare[123]
	CACNA1A	Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit	AD	Rare[95]
	CLCN4	Chloride voltage-gated channel 4	XL	Rare[133]
	EEF1A2	Eukaryotic translation elongation factor 1 alpha 2	AD	Rare[96, 97]
	FRRS1L	DOMON domain-containing protein FRRS1L	AR	Rare[135]
	GNAO1	Guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O	AD	Rare in epileptic encephalopathy and early-onset hyperkinetic movement disorders[136]
	IQSEC2	IQ motif and sec7 domain 7	XL	Rare[95]
	NR2F1	Nuclear receptor subfamily 2, group F, member 1	AD	Rare[103]
	QARS	Glutaminyl-tRNA synthetase	AR	Rare[104]
	SLC13A5	Solute carrier family 13(sodium-dependent citrate transporter), member 5	AR	Rare[108]
	SZT2	KICSTOR complex protein SZT2	AR	Rare[149]
	TBL1XR1	F-box-like/WD repeat-containing protein TBL1XR1	AD	Rare[150]
	PIGA	Phosphatidylinositol glycan anchor biosynthesis, class A	XL	Rare[109]
	PIGN	Phosphatidylinositol glycan anchor biosynthesis, class N	AR	Rare[145]
	PIGO	Phosphatidylinositol glycan anchor biosynthesis, class O	AR	Rare[110]
	PIGV	Phosphatidylinositol glycan anchor biosynthesis, class V	AR	Rare[111]
	LIAS	Lipoyl synthase, mitochondrial	AR	Rare[42]
	WWOX	WW domain containing oxidoreductase	AR	Rare[105]
	MAGI2 (dels only)	Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2	AD	Rare[43]
	SLC25A22	Mitochondrial glutamate carrier 1	AR	Rare[44]
	PLCB1 (dels only)	1-phoshatidylinositol 4,5-bisphosphate phosphodiesterase beta-1	AR	Rare[152]
	ATP6AP2	Renin receptor	XL	Rare[45]
Autosomal	*CHRNA4*	Neuronal acetylcholine receptor alpha-4	AD	~10% autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)[6]

Epilepsy Type	Gene	Protein	Inh	Diagnostic Yield in Selected Population(s)
Dominant Focal Epilepsies	*CHRNB2*	Neuronal acetylcholine receptor beta-2	AD	< 5% ADNFLE[6]
	CHRNA2	Neuronal acetylcholine receptor alpha-2	AD	Rare in ADNFLE[6]
	DEPDC5	DEP domain containing 5	AD	5-37% autosomal dominant focal epilepsies, with or without cortical dysplasia[126]
	KCNT1	Potassium channel, sodium activated subfamily T, member 1	AD	< 5% ADNFLE[99,102]
	LGI1	Leucine-rich glioma-inactivated protein 1	AD	~50% autosomal dominant partial epilepsy with auditory features (ADTLE)[6]
	NPRL3	GATOR complex protein NPRL3	AD	~2% autosomal dominant focal epilepsies, with or without cortical dysplasia[127]
Generalized Epilepsy with Febrile Seizures Plus (GEFS+)	*SCN1A*	Sodium channel protein type 1 alpha	AD	5-10% GEFS+[6]
	SCN1B	Sodium channel subunit beta-1	AD	<5% GEFS+[6]
	GABRG2	Gamma-aminobutyric acid receptor subunit gamma-2	AD	<1% GEFS+[6]
	SCN2A	Sodium channel protein type 2 alpha	AD	Rare[5]
Epilepsy with paroxysmal dyskinesia	*PRRT2*	Proline-rich transmembrane protein 2	AD	62-96% of familial PKD/infantile convulsions (PKD/IC); 36% sporadic PKD/IC[14,17,18]
	KCNMA1	Potassium calcium-activated channel subfamily M alpha 1	AD/AR	Rare[140]
Progressive Myoclonic Epilepsy	*EPM2A*	Laforin	AR	53% Lafora disease[48]
	NHLRC1	NHL repeat-containing protein 1 (malin)	AR	40% Lafora disease[48]
	CSTB (EPM1)*	Cystatin-B	AR	>90% Unverricht-Lundborg disease[49]
	KCTD7 (EPM3)	BTB/POZ domain-containing protein KCTD7	AR	Rare[50]
	SCARB2 (EPM4)	Lysosome membrane protein 2	AR	~7% progressive myoclonic epilepsy[51]; Unknown in action myoclonus-renal failure syndrome[52]
	GOSR2	Golgi SNAP receptor complex member 2	AR	Rare[53,54]
	KCNC1	Potassium voltage-gated channel subfamily C member 1	AD	Rare KCNC1-associated myoclonus epilepsy and ataxia (MEAK)[115]
	FOLR1	Folate receptor alpha	AR	Rare[55]
Rett/atypical Rett syndromes	*MECP2*	Methyl CpG binding protein 2	XL	88% females with Rett syndrome[57]
	CDKL5	Cyclin-dependent kinase-like 5	XL	2-8% females with atypical Rett syndrome[58,59]
	CTNNB1	Catenin beta 1	AD	Rare in Rett-like syndromes[116]
	DDX3X	DEAD-box helicase 3, X-linked	XL	Rare in Rett-like syndromes[117]
	*FOXG1***	Forkhead box protein G1	AD	~1% Rett syndrome overall[60]; 25% congenital variant of Rett[61]
	GABBR2	Gamma-aminobutyric acid type B receptor subunit 2	AD	Rare in epileptic encephalopathy and intellectual disability with Rett-like features[118]
	KCNA2	Potassium voltage-gated channel subfamily A member 2	AD	Rare in Rett-like syndromes[119]
	MBD5	Methyl-CpG-binding domain protein 5	AD	Rare in Rett-like syndromes[62]
	MEF2C	Myocyte-specific enhancer factor 2C	AD	Rare in Rett-like syndromes[63]
	SATB2	SATB homeobox 2	AD	Rare in Rett-like syndromes[120]
	STXBP1	Syntaxin binding protein 1	AD	Rare in Rett-like syndromes[121]

Epilepsy Type	Gene	Protein	Inh	Diagnostic Yield in Selected Population(s)
	TBL1XR1	Transducin (beta)-like 1 X-linked receptor 1	AD	Rare in Rett-like syndromes[122]
	WDR45	WD repeat domain 45	XL	Rare in Rett-like syndromes[106, 107]
Angelman/ Angelman-like/ Pitt-Hopkins syndromes	*UBE3A*	Ubiquitin protein ligase E3A	AD	68% maternally inherited 15q11.2 deletion[64]; 11% UBE3A sequencing variant Angelman syndrome[64]
	SLC9A6	Sodium/hydrogen exchanger 6	XL	6% Angelman-like syndrome[65]
	MBD5	Methyl-CpG-binding domain protein 5	AD	Rare in Angelman-like syndrome[66]
	TCF4	Transcription factor 4	AD	36% Pitt-Hopkins syndrome (PHS)[67]; 2% Angelman syndrome[67]
	ATRX	Transcriptional regulator ATRX	XL	95% males with alpha-thalassemia X-linked intellectual disability syndrome[153]
	NRXN1	Neurexin-1	AR	Rare in PHS[68]
	CNTNAP2	Contactin-associated protein-like 2	AR	Rare in PHS[68]
Mowat-Wilson syndrome	*ZEB2*	Zinc finger E-box-binding homeobox 2	AD	95% Mowat Wilson syndrome[69,70]
Creatine deficiency syndromes	*SLC6A8***	Solute carrier family 6 (neurotransmitter transporter), member 8	XL	2% males with epilepsy and intellectual disability[46]; 65% males with biochemical creatine deficiency[47]
	*GAMT***	Guanidinoacetate N-methyltransferase	AR	Rare[71]
	GATM	Glycine amidinotransferase, mitochondrial	AR	Rare[71]
Neuronal Ceroid Lipofuscinoses (NCL)	*PPT1 (CLN1)*	Palmitoyl-protein thioesterase 1	AR	98% PPT1 deficiency[72]
	TPP1 (CLN2)	Tripeptidyl-peptidase 1	AR	95% TPP1 deficiency[73]
	CLN3	Battenin	AR	92% Juvenile NCL[74]
	DNAJC5 (CLN4B)	DnaJ homolog subfamily C member 5	AD	25% Kufs disease[75,76]
	CLN5	Ceroid-lipofuscinosis neuronal protein 5	AR	94% Finnish late-infantile NCL[77]; Otherwise rare
	CLN6	Ceroid-lipofuscinosis neuronal protein 6	AR	Rare[77]
	MFSD8 (CLN7)	Major facilitator superfamily domain-containing protein 8	AR	Rare[77]
	CLN8	Ceroid-lipofuscinosis neuronal protein 8	AR	100% Finnish Northern epilepsy[77]; Otherwise rare
	CTSD (CLN10)	Cathepsin D	AR	Rare[77]
	CTSF (CLN13)	Cathepsin F	AR	Rare[77]
	KCTD7 (CLN14)	BTB/POZ domain-containing protein KCTD7	AR	Rare[78]
Metabolic disorders	*ALDH5A1*	Aldehyde dehydrogenase 5 family member A1	AR	96% SSADH deficiency[129]
	ADSL	Adenylosuccinate lyase	AR	Rare adenosuccinate lyase deficiency[79]
	ASNS	Asparagine synthetase (glutamine-hydrolyzing)	AR	Unknown (asparagine synthetase deficiency)[130]
	FOLR1	Folate receptor alpha	AR	Rare cerebral folate deficiency[56]
	GLDC	Glycine decarboxylase	AR	70-75% glycine encephalopathy (nonketotic hyperglycinemia)[124]
	NGLY1	N-glycanase 1	AR	Rare in congenital disorder of deglycosylation[143]
	SLC19A3	Solute carrier family 19 member 3	AR	Rare thiamine metabolism dysfunction disorders[125]
Periventricular	*FLNA*	Filamin A	XL	93% classic bilateral periventricular nodular

Epilepsy Type	Gene	Protein	Inh	Diagnostic Yield in Selected Population(s)
nodular heterotopia				heterotopia[134]
Kabuki syndrome	*KDM6A*	Lysine demethylase 6A	XL	Rare Kabuki syndrome[128]
EAST/SeSAME syndrome	*KCNJ10*	ATP-sensitive inward rectifier potassium channel 10	AR	Rare[81,82]
CLIFAHDD and infantile hypotonia with psychomotor retardation and characteristic facies (IHPRF)	*NALCN*	Sodium leak channel, non-selective	AD/AR	Rare[142]
Epilepsy and hemiplegic migraine	*ATP1A2*	Sodium/potassium-transporting ATPase subunit alpha-2	AD	Unknown[6]
Epilepsy and alternating hemiplegia of childhood	*ATP1A3*	Sodium/potassium-transporting ATPase subunit alpha-3	AD	Rare in early life epilepsy[131], 78% alternating hemiplegia of childhood[132]
Idiopathic generalized epilepsy	*CHRNA7 (dels only)*	Neuronal acetylcholine receptor subunit alpha-7	AD	~1% patients with IGE[56]
Epilepsy with learning, speech, and/or behavioral disorders	*GRIN2A*	Glutamate receptor ionotropic, NMDA 2A	AD	9-20% atypical Rolandic epilepsy and epilepsy-aphasia[89]; ~2% patients with intellectual disability and epilepsy[83,84]
	GRIN2B	Glutamate receptor ionotropic, NMDA 2B	AD	Unknown[83]
	KANSL1	KAT8 regulatory NSL complex subunit 1	AD	Unknown[85,86]
	DYRK1A	Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A	AD	Rare[93]
	EEF1A2	Eukaryotic translation elongation factor 1 alpha 2	AD	Rare[96]
	HNRNPU	HNRNPU antisense RNA 1	AD	Rare[137]
	KCNH1	Potassium voltage-gated channel subfamily H member 1	AD	Rare in Temple-Baraitser and Zimmermann-Laband syndromes[139]
	KIAA2022	Neurite extension and migration factor	XL	Rare[141]
	PACS1	Phosphofurin acidic cluster sorting protein 1	AD	Rare[144]
	PNKP	Bifunctional polynucleotide phosphatase/kinase	AR	Rare[86]
	PPP2R5D	protein phosphatase 2 regulatory subunit B', delta	AD	Rare[146]

* The dodecamer repeat expansion that accounts for ~90% of all CSTB mutations is not be detectable by this test

** Does not include deletion/duplication testing of DNM1, FOXG1, and SLC6A8; duplications of GAMT may not be detectable

References:

1. Berg et al. (2010) *Epilepsia* 51: 676-685. 2. Pellock, JM (2004) *Neurol* (2004) 62:S17-S23. 3. Pong et al., (2011) *Pediatr Neurol* 44:317-327. 4. Weber et al., (2008) *Dev Med Child Neurol* 50:648-654. 5. Nicita et al., (2011) *Seizure: Eur J Epilepsy* doi:10.1016/j.seizure.2011.08.007 6. Ottman et al., (2010) *Epilepsia* 51:655-670. 7. Pal et al., (2010) *Nat Rev Neurol* 6:445-453. 8. Deprez et al., (2009) *Neurol* 72:273-281. 9. Macdonald et al., (2010) *J Physiol* 588:1861-1869. 10. Andrade DM (2009) *Hum Genet* 126:173-193. 11. Ramachandran et al., (2009) *Epilepsia* 50:29-36. 12. Steinlein et al., (2004) *Nat Rev Neurosci* 5:401-408. 13. Bennett S. (2004) *Pharmacogenomics* 5:433-8. 14. Heron et al., (2012) Am J Hum Genet 90 :152-160. 15. Schubert et al., (2012) Hum Mutat 33:1439-1443. 16. Specchio et al., (2013) Eur J Pediatr Neurol 1:77-81. 17. Lee HY et al., (2012) Cell Reports 1:1-11. 18. Lee YC et al., (2012) PloS One 7 :e38543. 19. Falace et al., (2010) Am J Hum Genet 87:365-370. 20. Corbett et al., (2010) Am J Hum Genet 87:371-375. 21. Staley et al., (2011) Pediatr 127:e117-e125. 22. Dabora et al., (2001) Am J Hum Genet 68:64-80. 23. Au et al., (2007) Genet Med 9:88-100. 24. Zucca et al., (2008) Arch Neurol 65:489-494. 25. Harkin et al., (2007) Brain 130:843-852. 26. Higurashi et al., (2011) Epilepsy Res dio:10.1016/j.eplepsyres.2011.10.014. 27. Depienne et al., (2009) Plos Genet 5(2):e1000381. 28. Marini et al., (2010) Neurology 75:646-653.

29. Hynes et al., (2010) J Med Genet 47:211-216. 30. Depienne et al., (2010) Hum Mutat 32:E1959-E1975. 31. Weckhuysen et al., (2012) Ann Neurol 71:15-25. 32. Mills et al., (2010) Brain 133:2148-2159. 33. Nguyen et al., (2006) J Hepatol 45:108-116. 34. Isohanni et al., (2011) Neurol 76:811-815. 35. Hunter et al., (2011) Pediatr Neurol 45:311-318. 36. Bienvenu et al., (2013) Neurogenet 14:71-75. 37. Kamiya et al., (2004) J Neurosci 24(11):2690-2698. 38. Ogiwara et al., (2009) Clin Genet 73(13):1046-1053. 39. Veeramah et al., (2012) Am J Hum Genet 90:502-510. 40. Gospe et al., (2010) Chang Gung Med 33:1-12. 41. Saitsu et al., (2010) Am J Hum Genet 886:881-891. 42. Mayr et al., (2011) Am J Hum Genet 89:792-797. 43. Marshall et al., (2008) Am J Hum Genet 83:106-111. 44. Molinari et al., (2009) Clin Genet 76:188-194. 45. Ramser et al., (2005) Hum Molec Genet 14:1019-102721. 46. Mercimek-Mahmutoglu et al. (2009) Mol. Genet. Metab. 96 (4):273-5. 47. Comeaux et al. (2013) Molecular Genetics And Metabolism 109 (3):260-8 (PMID: 23660394). 48. Jansen and Andermann (Updated December 2007). Progressive Myoclonic Epilepsies, Lafora Type. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2010. Available at http://www.genetests.org. 49. Lehesjoki and Kalviainan (Updated June 2009) Unverricht-Lundborg Disease. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2010. Available at http://www.genetests.org. 50. Kousi et al., (2012) J Med Genet 49:391-399. 51. Dibbens et al., (2009) Ann Neurol 66:532-536. 52. Berkovic et al., (2008) Am J Hum Genet 82:673-684. 53. Corbett et al., (2011) Am J Hum Genet 82:673-684. 54. Lomax et al., (2013) Brain 136:1146-1154. 55. Grapp et al., (2012) Brain 135:2022-2031. 56. Helbig et al., (2009) Nat Genet 41:160-162. 57. Li et al., (2006) J Hum Genet 52:38-47. 58. Tao et al., (2004) Am J Hum Genet 75:1149-1154. 59. Rosas-Vargas et al., (2008) J Med Genet 45:172-178. 60. Bahi-Buisson et al., (2010) 11:241-249. 61. Mencarelli et al., (2010) J Med Genet 47:49-53. 62. Von Bon et al., (2010) Eur J Hum Genet 18:163-170. 63. Zweier et al., (2010) Hum Mutat 31:722-733. 64. Lossie, et al, (2001) J Med Genet 38(12):834-845. 65. Gillfillan et al., (2008) Am J Hum Genet 82: 1003-1010. 66. Jaillard et al., (2009) J Med Genet 46:847-855. 67. de Pontual et al., (2009) Hum Mutat 30:669-676. 68. Zweier et al., (2009) Am J Hum Genet 85:655-666. 69. Wilson et al., (2003) Am J Med Genet A 119A:257-265. 70. Zweier et al., (2005) Eur J Med Genet 48:97-111. 71. Braissant et al., (2011) Amino Acids 40:1315-1324. 72. Das et al., (1998) J Clin Invest 102:361-370. 73. Sleat et al., (1999) Am J Hum Genet 64:1511-1523. 74. Munroe et al., (1997) Am J Hum Genet 61:310-316. 75. Noskova et al., (2011) Am J Hum Genet 89:241-252. 76. Velinov et al., (2012) PloS One 7:e29729. 77. Mole and Williams (Updated March 2010). Neuronal Ceroid Lipofuscinosis. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2010. Available at http://www.genetests.org. 78. Staropoli et al., (2012) Am J Hum Genet 91:202-208. 79. Spiegel et al., (2006) Molec Genet Metab 89:19-31. 80. Grapp et al., (2012) Brain 135:2022-2031. 81. Brockenhauer et al., (2009) N Engl J Med 360:1960-1970. 82. Scholl et al., (2009) Proc Natl Acad Sci USA 106:5842-5847. 83. Endele et al., (2010) Nat Genet 42:1021-1026. 84. De Ligt et al., (2012) N Engl J Med 367:1921-1929. 85. Koolen et al., (2012) Nat Genet 44:639-641. 86. Zollino et al., (2012) Nat Genet 44:636-638. 87. Shen et al., (2010) Nat Genet 42:245-249. 88. Carvill et al., (2014) Neurol 82:1245-1253. 89. Lesca et al., (2013) Nat Genet 45:1061-1066. 90. Lemke et al., (2014) Ann Neurol 75:147-154. 91. Carvill et al. (2013) Nature Genetics 45 (7):825-30 (PMID: 23708187). 92. EuroEPINOMICS-RES et al. American Journal Of Human Genetics 95 (4):360-370 (PMID: 25262651). 93. Courcet et al. (2012) Journal Of Medical Genetics 49 (12):731-6 (PMID: 23099646) 94. Lemke et al. (2012) Epilepsia 53 (8):1387-98 (PMID: 22612257) 95. Allen et al. (2013) Nature 501 (7466):217-21 (PMID: 23934111) 96. Nakajima et al. (2014) Clinical Genetics : (PMID: 24697219) 97. Veeramah et al. (2013) Epilepsia 54 (7):1270-81 (PMID: 23647072). 98. Torkamani et al. (2014) Annals Of Neurology 76 (4):529-40 (PMID: 25164438) 99. Møller et al. (2015) Epilepsia : (PMID: 26122718) 100. Barcia et al. (2012) Nature Genetics 44 (11):1255-9 (PMID: 23086397) 101. McTague et al. (2013) Brain 136 (Pt 5):1578-91 (PMID: 23599387) 102. Heron et al. (2012) Nature Genetics 44 (11):1188-90 (PMID: 23086396) 103. Hino-Fukuyo et al. (2015) Human Genetics 134 (6):649-58 (PMID: 25877686) 104. Kodera et al. (2015) J. Hum. Genet. 60 (2):97-101 (PMID: 25471517) 105. Mignot et al. (2015) Journal Of Medical Genetics 52 (1):61-70 (PMID: 25411445) 106. Ohba et al. (2014) J. Hum. Genet. 59 (5):292-5 (PMID: 24621584) 107. Hayflick et al. (2013) Brain 136 (Pt 6):1708-17 (PMID: 23687123) 108. Hardies et al. (2015) Brain 138 (Pt 11):3238-50 (PMID: 26384929) 109. Tarailo-Graovac et al. (2015) Orphanet Journal Of Rare Diseases 10 (1):23 (PMID: 25885527) 110. Nakamura K et al. (2014) Epilepsia 55(2):e13-7.24417746 111. Horn et al. (2014) Eur. J. Hum. Genet. 22 (6):762-7 (PMID: 24129430) 112. Srivastava et al. (2014) American Journal Of Medical Genetics. Part A : (PMID: 25124326) 113. Wirrell et al., (2015) Epilepsia 56(4):617–625 114. EpiPM Consortium (2015) Lancet Neurol 14:1219–28. 115. Oliver et al. (2017) Ann. Neurol. 81 (5):677-689 (PMID: 28380698). 116. Percy et al. (2018) Transl Sci Rare Dis 3 (1):49-53 (PMID: 29682453). 117. Snijders et al. (2015) Am. J. Hum. Genet. 97 (2):343-52 (PMID: 26235985). 118. Yoo et al. (2017) Ann. Neurol. 82 (3):466-478 (PMID: 28856709). 119. Allou et al. (2017) Clin. Genet. 91 (3):431-440 (PMID: 27062609). 120. Zarate et al. (2018) Am. J. Med. Genet. A 176 (4):925-935 (PMID: 29436146) 121. Romaniello et al. (2015) Neuroreport 26 (5):254-7 (PMID: 25714420). 122. Saitsu et al. (2014) Journal Of Human Genetics 59 (10):581-3 (PMID: 25102098). 123. Au et al., (2007) Genet Med 9:88-100. 124. Ortigoza-Escobar et al. (2017) Ann. Neurol. 82 (3):317-330 (PMID: 28856750) 125. Van Hove J, Coughlin C II, Scharer G. Glycine Encephalopathy. 2002 Nov 14 [Updated 2013 Jul 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1357/. 126. Baulac et al. (2015) Ann. Neurol. 77 (4):675-83 (PMID: 25623524) 127. Weckhuysen et al. (2016) Epilepsia 57 (6):994-1003 (PMID: 27173016) 128. Bögershausen et al. (2016) Hum. Mutat. 37 (9):847-64 (PMID: 27302555) 129. Akaboshi et al. (2003) Human Mutation 22 (6):442-50 (PMID: 14635103) 130. Gupta et al. (2017) Metab Brain Dis 32 (6):1889-1900 (PMID: 28776279) 131. Paciorkowski et al. (2015) Epilepsia 56 (3):422-30 (PMID: 25656163) 132. Heinzen et al. (2012) Nature Genetics 44 (9):1030-4 (PMID: 22842232) 133. Palmer et al. (2018) Mol. Psychiatry 23 (2):222-230 (PMID: 27550844) 134. . Chen MH, Walsh CA. FLNA-Related Periventricular Nodular Heterotopia. 2002 Oct 8 [Updated 2015 Sep 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1213/ 135. Madeo et al. (2016) Am. J. Hum. Genet. 98 (6):1249-55 (PMID: 27236917) 136. Danti et al. (2017) Neurol Genet 3 (2):e143 (PMID: 28357411) 137. Bramswig et al. (2017) Hum. Genet. 136 (7):821-834 (PMID: 28393272) 138. Masnada et al. (2017) Brain 140 (9):2337-2354 (PMID: 29050392) 139. Mégarbané et al. (2016) BMC Med. Genet. 17 (1):42 (PMID: 27282200) 140. Webster et al. (2017) Clin. Genet. 91 (5):756-763 (PMID: 27568816) 141. Webster et al. (2017) Clin.

Genet. 91 (5):756-763 (PMID: 27568816) 142. Bend et al. (2016) Neurology 87 (11):1131-9 (PMID: 27558372) 143. Enns et al. (2014) Genet. Med. 16 (10):751-8 (PMID: 24651605) 144. Schuurs-Hoeijmakers et al. (2016) Am. J. Med. Genet. A 170 (3):670-5 (PMID: 26842493) 145. Fleming et al. (2016) Am. J. Med. Genet. A 170 (1):77-86 (PMID: 26394714) 146. Shang et al. (2016) Neurogenetics 17 (1):43-9 (PMID: 26576547) 147. Reijnders et al. (2018) J. Med. Genet. 55 (2):104-113 (PMID: 29097605) 148. Carvill et al. (2015) Am. J. Hum. Genet. 96 (5):808-15 (PMID: 25865495) 149. Tsuchida et al. (2018) Clin. Genet. 93 (2):266-274 (PMID: 28556953) 150. Saitsu et al. (2014) Journal Of Human Genetics 59 (10):581-3 (PMID: 25102098) 151. Moog U, Uyanik G, Kutsche K. CASK-Related Disorders. 2013 Nov 26. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK169825/ 151. Mignot et al. (2016) J. Med. Genet. 53 (8):511-22 (PMID: 26989088) 152. Ngoh et al. (2014) Dev Med Child Neurol 56 (11):1124-8 (PMID: 24684524) 153. Stevenson RE. Alpha-Thalassemia X-Linked Intellectual Disability Syndrome. 2000 Jun 19 [Updated 2014 Nov 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1449/

Appendix: Genes Included on Comprehensive Epilepsy Panel and Subpanels

Gene	Comprehensive	Infantile	Childhood	STAT	Progressive	Rett/Angelman
ADSL	□	□	□			
ALDH5A1	□	□	□			
ALDH7A1	□	□		□		
ALG13	□	□				
ARHGEF9	□	□				
ARX	□	□		□		
ASNS	□	□				
ATP1A2	□					
ATP1A3	□	□	□			
ATP6AP2	□	□				
ATRX	□	□	□			□
BRAT1	□	□		□		
CACNA1A	□	□	□			
CASK	□	□	□	□		
CDKL5	□	□	□	□		□
CHD2	□	□	□			
CHRNA2	□		□			
CHRNA4	□		□			
CHRNA7**	□	□	□			
CHRNB2	□		□			
CLCN4	□	□	□			
CLN3	□	□	□		□	
CLN5	□	□	□		□	
CLN6	□	□			□	
CLN8	□	□			□	
CNTNAP2	□	□				□
CSTB***	□				□	
CTNNB1	□					□
CTSD (CLN10)	□	□	□		□	
CTSF	□				□	
DDX3X	□	□	□			□
DEPDC5	□	□	□			
DNAJC5 (CLN4B)	□				□	
DNM1*	□	□				
DYRK1A	□	□	□			
EEF1A2	□	□	□			
EHMT1	□	□	□			
EPM2A	□		□		□	
FLNA	□					
FOLR1	□	□	□	□	□	
FOXG1*	□	□	□			□
FRRS1L	□	□				
GABBR2	□	□				□
GABRA1	□	□	□			
GABRB2	□	□	□			
GABRB3	□	□	□			
GABRG2	□	□	□			
GAMT*	□	□	□			
GATM	□	□	□			
GLDC	□	□		□		
GNAO1	□	□	□			
GOSR2	□		□			
GRIN1	□	□	□		□	
GRIN2A	□	□	□			
GRIN2B	□	□				

Gene	Comprehensive	Infantile	Childhood	STAT	Progressive	Rett/Angelman
HNRNPU	□	□				
IQSEC2	□	□	□			
KANSL1	□	□	□			
KCNA2	□	□	□			□
KCNB1	□	□				
KCNC1	□		□		□	
KCNH1	□	□				
KCNJ10	□	□				
KCNMA1	□	□	□			
KCNQ2	□	□		□		
KCNQ3	□	□		□		
KCNT1	□	□	□	□		
KCTD7 (CLN14)	□	□	□		□	
KDM6A	□	□	□			
KIAA2022	□	□	□			
LGI1	□		□			
MAGI2**	□	□	□			
MBD5	□	□	□			□
MECP2	□	□	□	□		□
MEF2C	□	□	□	□		□
MFSD8 (CLN7)	□		□		□	
NALCN	□	□	□			
NGLY1	□	□	□			
NHLRC1 (EPM2B)	□		□		□	
NPRL3	□	□	□			
NR2F1	□	□				
NRXN1	□	□	□			□
PACS1	□	□	□			
PCDH19	□	□	□	□		
PIGA	□	□				
PIGN	□	□	□			
PIGO	□	□				
PIGV	□	□				
PLCB1**	□	□				
PNKP	□	□	□			
PNPO	□	□		□		
POLG	□	□	□	□		
PPP2R5D	□	□	□			
PPT1 (CLN1)	□	□	□		□	
PRRT2	□	□				
PURA	□	□	□			
QARS	□	□				
SATB2	□					□
SCARB2	□				□	
SCN1A	□	□	□	□		
SCN1B	□	□	□	□		
SCN2A	□	□	□	□		
SCN8A	□	□		□		
SLC13A5	□	□				
SLC19A3	□	□	□	□		
SLC25A22	□	□				
SLC2A1	□	□	□	□		
SLC6A1	□	□	□			
SLC6A8*	□	□	□	□		
SLC9A6	□	□	□			□
SMC1A	□	□	□			
SPATA5	□	□	□			

Gene	Comprehensive	Infantile	Childhood	STAT	Progressive	Rett/Angelman
SPTAN1	□	□		□		
STX1B	□	□	□			
STXBP1	□	□		□		□
SYNGAP1	□	□	□			
SZT2	□	□				
TBC1D24	□	□	□			
TBL1XR1	□	□				□
TCF4	□	□	□			□
TPP1 (CLN2)	□	□	□	□	□	
TSC1	□	□		□		
TSC2	□	□		□		
UBE3A	□	□	□			□
WDR45	□	□	□			□
WWOX	□	□				
ZEB2	□	□	□			□

* Sequencing only (no deletion/duplication analysis) for DNM1, FOXG1, or SLC6A8. This test can detect only complete gene deletions/duplications of GAMT. No sequence coverage of exon 22 of DNM1 (NM_004408.3).

** Deletion/duplication testing only (no sequence analysis) for CHRNA7, MAGI2, and PLCB1.

*** The dodecamer repeat expansion that accounts for ~90% of all CSTB mutations is not be detectable by this test.